title: A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease.
abstract: Nonalcoholic fatty liver disease (NAFLD) is a common liver disease that can progress to cirrhosis and liver failure. Anthocyanin, a member of the flavonoid family, has been shown to ameliorate NAFLD-associated pathologies in rodents.The aim of this CONSORT-compliant pilot study is to evaluate the effects of anthocyanin supplementation on insulin resistance and liver injury biomarkers in patients with NAFLD.A total of 74 subjects with NAFLD were divided into 2 groups in this double-blind, randomized study. Patients received either purified anthocyanin (320 mg/d) derived from bilberry and black currant or placebo for 12 weeks. Diet, physical activity, anthropometric parameters, glucose tolerance, and a set of biomarkers related to NAFLD were evaluated before and after intervention.No significant differences were observed in nutrient intake, physical activity, anthropometric parameters, or plasma lipid profile between patients receiving anthocyanin or placebo. Compared to controls, the anthocyanin group exhibited significant decreases (P < 0.05, all comparisons) in plasma alanine aminotransferase (-19.1% vs 3.1%), cytokeratin-18 M30 fragment (-8.8% vs 5.6%) and myeloperoxidase (-75.0% vs -44.8%). Significant decreases from baseline in fasting blood glucose and homeostasis model assessment for insulin resistance were observed in the anthocyanin group; however, these differences were not significant relative to placebo controls. In addition, the oral glucose tolerance test indicated that anthocyanin supplementation significantly decreased the 2-hour loading glucose level compared to control (-18.7% vs -3.8%, P = 0.02).A 12-week supplement of purified anthocyanin improved insulin resistance, indicators of liver injury, and clinical evolution in NAFLD patients. Further studies are warranted to determine the clinical applications of anthocyanin in NAFLD.This trial was registered at clinicaltrials.gov as NCT01940263.
authors.affiliation: From the Department of Nutrition (P-WZ, H-HG), Henry Fok School of Food Science and Engineering, Shaoguan University, Shaoguan; Department of Nutrition (P-WZ, DL, W-HL), School of Public Health, Sun Yat-Sen University, Guangzhou; and Department of Software Engineering (F-XC), School of Information Science and Engineering, Shaoguan University, Shaoguan, China.
authors.forename: Pei-Wen
authors.initials: PW
authors.lastname: Zhang
authors.forename: Feng-Xia
authors.initials: FX
authors.lastname: Chen
authors.forename: Di
authors.initials: D
authors.lastname: Li
authors.forename: Wen-Hua
authors.initials: WH
authors.lastname: Ling
authors.forename: Hong-Hui
authors.initials: HH
authors.lastname: Guo
mesh_terms: D000328:Adult; D000872:Anthocyanins / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007333:Insulin Resistance; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D010865:Pilot Projects; D014280:Triglycerides / Q000097:blood
chemical_list: D000872:Anthocyanins; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol